Rebus (RBSH) 10-K 6 Aug 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	Inspyr Therapeutics, Inc.
Entity Central Index Key	0001421204
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Transition Period	false
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	DE
Entity File Number	000-55331
Entity Public Float			$ 166,389
Entity Common Stock, Shares Outstanding		150,000,000

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash	$ 4	$ 10
Restricted cash	327
Prepaid expenses		5
Total current assets	331	15
Office and lab equipment, net of accumulated depreciation of $5 and $2	2	4
Intangible assets, net of accumulated amortization of $179 and $162	33	50
Total assets	366	69
Current liabilities:
Accounts payable	2,085	1,968
Accrued expenses	1,814	1,539
Convertible debentures, net of unamortized discount of $281 and $227	2,600	2,476
Derivative liability	2,134	2,934
Total current liabilities	8,633	8,917
Total liabilities	8,633	8,917
Commitments and contingencies (Note 8)
Stockholders' deficit:
Convertible preferred stock, par value $.0001 per share; 30,000,000 shares authorized, 495 and 495 shares issued and outstanding, respectively
Common stock, par value $.0001 per share; 150,000,000 shares authorized, 84,563,929 and 10,888,929 shares issued and outstanding, respectively	8	1
Additional paid-in capital	51,471	50,885
Accumulated deficit	(59,746)	(59,734)
Total stockholders' deficit	(8,267)	(8,848)
Total liabilities and stockholders' deficit	$ 366	$ 69

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Office and lab equipment, accumulated depreciation	$ 5	$ 2
Intangible assets, accumulated amortization	179	162
Net of unamortized discount of, convertible debentures	$ 281	$ 227
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized	30,000,000	30,000,000
Convertible preferred stock, shares issued	495	495
Convertible preferred stock, shares outstanding	495	495
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	84,563,929	10,888,929
Common stock, shares outstanding	84,563,929	10,888,929

Consolidated Statements of Loss

Consolidated Statements of Losses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating expenses:
Research and development	$ 208	$ 1,695
General and administrative	516	1,665
Impairment of goodwill		2,159
Impairment of equipment		332
Total operating expenses	724	5,851
Loss from operations	(724)	(5,851)
Other income (expense):
Gain (loss) on change in fair value of derivative liability	1,052	(103)
Gain on conversion of debt	210	88
Interest (expense), net	(550)	(5,234)
Loss before provision for income taxes	(12)	(11,100)
Provision for income taxes
Net loss	(12)	(11,100)
Deemed dividend	(196)	(2,204)
Net loss attributable to common shareholders	$ (208)	$ (13,304)
Net loss per common share, basic and diluted	$ (0.01)	$ (2.74)
Weighted average shares outstanding	23,242,710	4,855,784

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Deficit - USD ($) $ in Thousands	Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at beginning at Dec. 31, 2016			$ 47,746	$ (48,634)	$ (888)
Balance at beginning (in shares) at Dec. 31, 2016	2,828	1,398,832
Stock-based compensation			202		202
Conversion of preferred stock to common stock
Conversion of preferred stock to common stock (in shares)	(118)	223,585
Preferred stock exchanged for convertible notes payable
Preferred stock exchanged for convertible notes payable (in shares)	(2,505)
Conversion of notes			155		155
Conversion of notes (in shares)		2,144,340
Common stock issued for acquisition		$ 1	2,492		2,493
Common stock issued for acquisition (in shares)		7,122,172
Sale of preferred stock and warrants			285		285
Sale of preferred stock and warrants (in shares)	285
Preferred stock and warrants issued for services			5		5
Preferred stock and warrants issued for services (in shares)	5
Net loss				(11,100)	(11,100)
Balance at ending at Dec. 31, 2017		$ 1	50,885	(59,734)	(8,848)
Balance at ending (in shares) at Dec. 31, 2017	495	10,888,929
Stock-based compensation			90		90
Conversion of notes		$ 7	496		503
Conversion of notes (in shares)		73,675,000
Net loss				(12)	(12)
Balance at ending at Dec. 31, 2018		$ 8	$ 51,471	$ (59,746)	$ (8,267)
Balance at ending (in shares) at Dec. 31, 2018	495	84,563,929

Consolidated Statement of Sto_2

Consolidated Statement of Stockholders' Deficit (Parenthetical)	Dec. 31, 2017$ / shares
Statement of Stockholders' Equity [Abstract]
Share price (in dollars per share)	$ 1

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (12)	$ (11,100)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	19	40
Stock-based compensation	90	207
(Gain) loss on change in fair value of derivative liability	(1,052)	103
Gain on conversion of debt	(210)	(88)
Amortization of debt discount	486	93
Finance cost	64	5,137
Impairment of goodwill		2,159
Impairment of equipment		332
Decrease in operating assets:
Prepaid expenses and other assets	4	114
Increase in operating liabilities:
Accounts payable and accrued expenses	407	1,911
Cash used in operating activities	(204)	(1,092)
Cash flows from investing activities:
Cash from acquisition		23
Acquisition of office equipment		(3)
Cash provided by investing activities		20
Cash flows from financing activities:
Proceeds from convertible notes	525	250
Proceeds from sale of stock and warrants		285
Cash provided by financing activities	525	535
Net increase (decrease) in cash and restricted cash	321	(537)
Cash and restricted cash, beginning of year	10	547
Cash and restricted cash, end of year	$ 331	$ 10

Background

Background	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BACKGROUND	NOTE 1 – BACKGROUND Inspyr Therapeutics, Inc. ("we", "us", "our company", "our", "Inspyr" or the "Company") was formed under the laws of the State of Delaware in November 2003, and has its principal office in Westlake Village, California. We are an early-stage, pre-revenue, pharmaceutical company focused on the discovery and development of prodrug cancer therapeutics for the treatment of solid tumors, including brain, liver, prostate and other cancers. We plan to develop a series of therapies based on our target-activated prodrug technology platform. We are a clinical-stage, pre-revenue, pharmaceutical company primarily focused on the development of therapeutics for the treatment of diseases. Through our acquisition of Lewis and Clark Pharmaceuticals, Inc., we currently are focusing on a pipeline of small molecule adenosine receptor modulators. The adenosine receptor modulators include A 2B 2A 2B 2A During February 2018, due to a lack of capital, we curtailed our business operations. In the event that we are able to raise sufficient capital, our major focus would be to: (i) further characterization, in conjunction with Ridgeway Therapeutics, of anti-cancer activity of the current pipeline of A 2B 2A 2B 2A 2B 2A 2B 2A Our ability to execute our business plan is dependent on the amount and timing of cash, if any, that we are able to raise. During February of 2018, we curtailed our operations due to our lack of cash. During July 2018, we were able to raise approximately $500,000 through the sale of debt securities and we raised $25,000 in December 2018 through the sale of notes. We are currently using such funds to attempt to become current in our SEC reporting requirements, pay outstanding invoices to our independent registered accounting firm, and other outstanding obligations, the payment of which we believe to be vital to our future operations. Should we fail to further raise sufficient funds to execute our business plan, our priority would be to maintain our intellectual property portfolio and continue, to the best of our ability, our public company reporting requirements.

Management's Plans to Continue

Management's Plans to Continue as a Going Concern	12 Months Ended
	Dec. 31, 2018
Management Plans to Continue as Going Concern [Abstract]
MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN	NOTE 2 – MANAGEMENT'S PLANS TO CONTINUE AS A GOING CONCERN Basis of Presentation The opinion of our independent registered accounting firm on our financial statements contains explanatory going concern language. We have prepared our financial statements on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred losses since inception and have an accumulated deficit of $60 million as of December 31, 2018. We anticipate incurring additional losses for the foreseeable future until such time, if ever, that we can generate significant sales from our therapeutic product candidates which are currently in development or we enter into cash flow positive business development transactions. To date, we have generated no sales or revenues, have incurred significant losses and expect to incur significant additional losses as we advance mipsagargin through clinical studies. Consequently, our operations are subject to all the risks inherent in the establishment of a pre-revenue business enterprise as well as those risks associated with a company engaged in the research and development of pharmaceutical compounds. Our cash and restricted cash balances at December 31, 2018 was approximately $331,000, representing 90.4% of our total assets. Based on our current expected level of operating expenditures, we expect to be able to fund our operations into the third quarter of 2019. We curtailed operations in February 2018. We will require additional cash to fund and continue our operations beyond that point. This period could be shortened if there are any unanticipated increases in planned spending on development programs or other unforeseen events. We anticipate raising additional funds through collaborative arrangements, licensing agreements, public or private sales of debt or equity securities, or some combination thereof. There is no assurance that any such arrangement will be entered into or that financing will be available when needed in order to allow us to continue our operations, or if available, on terms favorable or acceptable to us. We raised approximately $500,000 in July 2018 and $25,000 in December 2018, which we expect will enable us to bring our required annual and quarterly filings current, which will enable us to seek additional financing. In the event additional financing is not obtained, we may pursue cost cutting measures as well as explore the sale of selected assets to generate additional funds. If we are required to significantly reduce operating expenses and delay, reduce the scope of, or eliminate any of our development programs or clinical trials, these events could have a material adverse effect on: our business, results of operations, and financial condition. These factors raise significant doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Our auditors' report issued in connection with our December 31, 2018 financial statements expressed an opinion that our capital resources as of the date of their audit report were not sufficient to sustain operations or complete our planned activities for the upcoming year unless we raised additional funds. Accordingly, our current cash level raises substantial doubt about our ability to continue as a going concern past the third quarter of 2019. If we do not obtain additional funds by such time, we may no longer be able to continue as a going concern and will cease operation which means that our shareholders will lose their entire investment.

Summary of Critical Accounting

Summary of Critical Accounting Policies and Use of Estimates	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES	NOTE 3 – SUMMARY OF CRITICAL ACCOUNTING POLICIES AND USE OF ESTIMATES Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates. Research and Development Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs. We incurred research and development expenses of $0.2 million and $1.7 million for the years ended December 31, 2018 and 2017, respectively. Cash Equivalents For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts. We did not have any cash equivalents at December 31, 2018 or 2017. Restricted Cash Restricted cash consists of funds held in trust for the Company. The use of these funds is restricted to: (i) the payment of professional fees in connection with bringing the Company's filings current, and (ii) the payment of vendors associated with the issuance and trading of the Company's securities, such as transfer agent fees and fees payable to the OTCQB and FINRA. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash and restricted cash was $0.3 million and $0.01 million at December 31, 2018 and 2017, respectively. As of December 31, 2018 and 2017, there was no cash over the federally insured limit. Intangible Assets Intangible assets consist of licensed technology, patents, and patent applications (see Note 5). The assets associated with licensed technology are recorded at cost and are being amortized on the straight line basis over their estimated useful lives of twelve to seventeen years. Office and Lab Equipment Equipment is stated at cost less accumulated depreciation. Depreciation is calculated on the straight line basis over the estimated useful lives of the assets of three to seven years. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to expense. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its equipment for impairment. Due to the suspension of business activity in February 2018, the Company determined that the office and lab equipment acquired pursuant to the Lewis & Clark, Pharmaceuticals, Inc. acquisition had become fully impaired as of December 31, 2017. Accordingly, we recorded an impairment charge of $0.3 million during the year ended December 31, 2017. Depreciation expense was approximately $2,000 and $23,000 for the years ended December 31, 2018 and 2017, respectively. Loss per Share Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of December 31, 2018 and 2017, as they would be anti-dilutive: Year Ended December 31, 2018 2017 Shares underlying options outstanding 323,514 356,280 Shares underlying warrants outstanding 2,512,930 3,045,740 Shares underlying convertible notes outstanding 828,337,812 135,122,128 Shares underlying convertible preferred stock outstanding 26,395,624 18,324,050 857,569,880 156,848,198 Derivative Liability The Company has financial instruments that are considered derivatives or contain embedded features subject to derivative accounting. Embedded derivatives are valued separately from the host instrument and are recognized as derivative liabilities in the Company's balance sheet. The Company measures these instruments at their estimated fair value and recognizes changes in their estimated fair value in results of operations during the period of change. The Company values its derivative liabilities using the Black-Scholes option valuation model. The resulting liability is valued at each reporting date and the change in the liability is reflected as change in derivative liability in the statement of operations. Goodwill Our goodwill consists of the excess purchase price paid in business combinations over the fair value of assets acquired. Goodwill is considered to have an indefinite life. The Company has decided to perform its annual goodwill and impairment assessment on December 31st of each year. The Company employs the non-amortization approach to account for goodwill. Under the non-amortization approach, goodwill is not amortized into the results of operations, but instead is reviewed annually or more frequently if events or changes in circumstances indicate that the asset might be impaired, to assess whether the fair value exceeds the carrying value. When evaluating the potential impairment of goodwill, we first assess a range of qualitative factors, including but not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for the Company's products and services, regulatory and political developments, entity specific factors such as strategy and changes in key personnel, and the overall financial performance for each of the Company's reporting units. If, after completing this assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then proceed to a two-step impairment testing methodology using the income approach (discounted cash flow method). In the first step of the two-step testing methodology, we compare the carrying value of the reporting unit, including goodwill, with its fair value, as determined by its estimated discounted cash flows. If the carrying value of a reporting unit exceeds its fair value, we then complete the second step of the impairment test to determine the amount of impairment to be recognized. In the second step, we estimate an implied fair value of the reporting unit's goodwill by allocating the fair value of the reporting unit to 100% of the assets and liabilities other than goodwill (including any unrecognized intangible assets). If the carrying value of a reporting unit's goodwill exceeds its implied fair value, the Company records an impairment loss equal to the difference in that period. When required, we arrive at our estimates of fair value using a discounted cash flow methodology which includes estimates of future cash flows to be generated by specifically identified assets, as well as selecting a discount rate to measure the present value of those anticipated cash flows. Estimating future cash flows requires significant judgment and includes making assumptions about projected growth rates, industry-specific factors, working capital requirements, weighted average cost of capital, and current and anticipated operating conditions. The use of different assumptions or estimates for future cash flows could produce different results. Due to the suspension of business activity in February 2018, the Company determined that the goodwill assigned to the Lewis & Clark, Pharmaceuticals, Inc. acquisition had become fully impaired as of December 31, 2017. Accordingly, we recorded a goodwill impairment charge of $2.2 million during the year ended December 31, 2017. Fair Value of Financial Instruments Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of three months or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts. The derivative liability consists of our convertible notes with a variable conversion feature. The Company uses the Black-Scholes option-pricing model to value its derivative liability which incorporate the Company's stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life. Fair Value Measurements The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability's classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company has recorded a derivative liability for its convertible notes with a variable conversion feature as of December 31, 2018. The tables below summarize the fair values of our financial liabilities as of December 31, 2018 (in thousands): Fair Value at Fair Value Measurement Using 2018 Level 1 Level 2 Level 3 Derivative liability $ 2,134 $ — $ — $ 2,134 The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands): Year ended December 31, 2018 2017 Balance at beginning of year $ 2,934 $ — Additions to derivative instruments 604 2,952 Reclassification on conversion (352 ) (121 ) Loss (gain) on change in fair value of derivative liability (1,052 ) 103 Balance at end of period $ 2,134 $ 2,934 Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible. Stock-Based Compensation We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to non-employees is determined in accordance with the fair value of the consideration received or the fair value of the equity instruments issued, whichever is a more reliable measurement. Compensation expense for awards granted to non-employees is re-measured on each accounting period. Determining the appropriate fair value of stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation and the volatility of our stock price. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life. Effect of ASU No. 2017-11 on Previously Issued Financial Statements In July 2017, the Financial Accounting Standards Board ("FASB") issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): Part 1 – Accounting for Certain Financial Instruments with Down Round Features and Part 2 – Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with Scope Exception ("ASU No. 2017-11"). Part 1 of ASU No. 2017-11 addresses the complexity of accounting for certain financial instruments with down round features. Down round features are provisions in certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of ASU No. 2017-11 addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification®. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. For public business entities, the amendments in Part I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company has early adopted the guidance under ASU 2017-11 for the year end December 31, 2017. Recent Accounting Pronouncements With the exception of those discussed below, there have not been any recent changes in accounting pronouncements and Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB) during the year ended December 31, 2018 that are of significance or potential significance to the Company. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company does not expect any impact from the adoption of this standard on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU No. 2017-04"). ASU No. 2017-04 simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. A public business entity that is a SEC filer should adopt the amendments of ASU No. 2017-04 for its annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not expect any impact from the adoption of this standard on its consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, "Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting", which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. If an award is not probable of vesting at the time a change is made, the new guidance clarifies that no new measurement date will be required if there is no change to the fair value, vesting conditions, and classification. This ASU will be applied prospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The adoption of this standard did not have a material impact on its consolidated financial statements.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2018
Supplemental Cash Flow Information [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	NOTE 4 – SUPPLEMENTAL CASH FLOW INFORMATION The following table contains additional information for the periods reported (in thousands). Year Ended December 31, 2018 2017 Non-cash financial activities: Common stock issued on conversion of notes payable and derivative liability $ 503 $ 155 Debentures converted to common stock 361 122 Derivative liability extinguished upon conversion of notes payable 352 121 Derivative liability issued 604 2,952 Net assets and liabilities recognized with the acquisition of Lewis and Clark Pharmaceuticals, Inc. — 2,493 Accounts payable paid through issuance of debentures 15 70 Debentures issued to retire preferred stock — 2,505 Preferred stock and warrants issued for fees — 5 There was no cash paid for interest and income taxes for the years ended December 31, 2018 and 2017.

Intellectual Property

Intellectual Property	12 Months Ended
	Dec. 31, 2018
Intellectual Property Abstract
INTELLECTUAL PROPERTY	NOTE 5 – INTELLECTUAL PROPERTY We solely own or have exclusive licenses to all of our patents and patent applications. Between 2008 and 2011, we entered into license and assignment agreements with Johns Hopkins University (JHU), the University of Copenhagen (UC) and certain co-inventors (Assignee Co-Founders), in which we paid $212,000 in cash and common stock. As a result of these payments and pursuant to the agreements, we acquired worldwide, exclusive, fully paid up rights in know-how, pre-clinical data, development data and certain patent portfolios that relate to, and form the basis of, our technology. Under these agreements, we are not required to make any other future payments, including fees or other reimbursements, milestones, or royalties, to JHU, UC, or the Assignee Co-Founders. Amortization expense recorded during the years ended December 31, 2018 and 2017 was approximately $17,000 for both years. Amortization expense is estimated to be approximately $17,000 for each one of the next two fiscal years.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2018
Accrued Liabilities, Current [Abstract]
ACCRUED EXPENSES	NOTE 6 – ACCRUED EXPENSES Accrued expenses consist of the following (in thousands): December 31, 2018 2017 Accrued compensation and benefits $ 1,326 $ 1,154 Accrued research and development 188 144 Accrued other 300 241 Total accrued expenses $ 1,814 $ 1,539

Derivative Liability

Derivative Liability	12 Months Ended
	Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITY	NOTE 7 – DERIVATIVE LIABILITY We account for equity-linked financial instruments, such as our convertible preferred stock, convertible debentures and our common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the respective agreement. Equity-linked financial instruments are accounted for as derivative liabilities, in accordance with ASC Topic 815 – Derivatives and Hedging, if the instrument allows for cash settlement or issuance of a variable number of shares. We classify derivative liabilities on the balance sheet at fair value, and changes in fair value during the periods presented in the statement of operations, which is revalued at each balance sheet date subsequent to the initial issuance of the stock warrant. In September 2017, July 2018 and December 2018, we issued convertible debentures and notes which contain a variable conversion feature, anti-dilution protection and other conversion price adjustment provisions. As a result, the Company assessed its outstanding equity-linked financial instruments and concluded that the convertible notes are subject to derivative accounting. The fair value of the conversion feature is classified as a liability in the financial statements, with the change in fair value during the periods presented recorded in the statement of operations. During the years ended December 31, 2018 and 2017, we recorded a gain of approximately $1.1 million and a loss of approximately $0.1 million, respectively, related to the change in fair value of the derivative liabilities during the periods. For purpose of determining the fair market value of the derivative liability, the Company used Black Scholes option valuation model. The significant assumptions used in the Black Scholes valuations of the derivatives at December 31, 2018 are as follows: 2018 Volatility 204 % Expected term (years) 8 months Risk-free interest rate 2.59 % Dividend yield None As of December 31, 2018 and 2017, the derivative liability recognized in the financial statements was approximately $2.1 million and $2.9 million, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 – COMMITMENTS AND CONTINGENCIES Operating Leases Inspyr currently does not have any ongoing leases for office space. It has availability to office space on an as needed basis. Its employees work on a remote basis. Rent expense for office space amounted to approximately $0 and $52,000 for the years ended December 31, 2018 and 2017, respectively. Employment Agreements We employ our Chief Executive Officer pursuant to a written employment agreement. The employment agreement contains severance provisions and indemnification clauses. The indemnification agreement provides for the indemnification and defense of the executive officer, in the event of litigation, to the fullest extent permitted by law. On February 28, 2017, Russell Richerson, PhD, resigned as chief operating officer of the Company, effective immediately. Dr. Richerson entered into a separation release of claims agreement ("Separation Agreement") pursuant to which the Company: (i) issued Dr. Richerson a warrant to purchase 76,726 shares of Common Stock with an exercise price of $0.75 per share and a term of three and a half (3.5) years, (ii) agreed to make the vested portion of any options held by Dr. Richerson, exercisable at any time during their remaining term regardless of any termination provisions contained in the applicable equity compensation plans pursuant to which such awards were made (collectively, the "Awards") and (iii) agreed to reduce the exercise prices of such Awards to $0.75 per share for the duration of their respective terms. In consideration of the foregoing, Dr. Richerson agreed to release the Company from any and all claims, including any rights or obligations as contained in his prior employment agreement, as amended. Severance provisions are not applicable to any other executive officer employment agreements until such time as they have each been employed for at least 6 months and the Company has raised $25 million in gross proceeds from capital raising transactions. Severance provisions pursuant to a termination within 12 months of a Sale Event occurring are not applicable as of December 31, 2018, as no Sale Event has occurred prior to such date. Legal Matters On March 16, 2016, Dr. Craig Dionne provided us his notice of termination as the company's Chief Executive Officer and Chief Financial Officer. Dr. Dionne's notice of termination states that such termination was for "Good Reason" as a result of a material change in his authority, functions, duties and responsibilities as chief executive officer. In the event that termination was for "Good Reason", Dr. Dionne would be entitled to certain severance payments as well as other benefits. The notice of termination, in additional to requesting such severance, also requests the payment of Dr. Dionne's annual and long term bonus for 2014 and 2015. While the Company disputes that the termination was for "Good Reason," as well as the amount of the bonuses due Dr. Dionne, if any, at this time the Company is unable to predict the financial outcome of this matter, and any views formed as to the viability of these claims or the financial liability which could result may change from time to time as the matter proceeds through its course. The Company is uncertain whether any litigation may result from the foregoing and the outcome of any such litigation is uncertain. The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.

Capital Stock and Stockholders'

Capital Stock and Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity Note [Abstract]
CAPITAL STOCK AND STOCKHOLDER'S EQUITY	NOTE 9 – CAPITAL STOCK AND STOCKHOLDERS' EQUITY Preferred Stock During December 2018, we designated 5,000 shares of preferred stock as Series D 0% Convertible Preferred Stock (the "Preferred Stock"). Each share of Preferred Stock shall have a par value of $0.0001 per share and a stated value equal to $1.00 (the "Stated Value"). With respect to a vote of stockholders to approve a reverse split of the Common Stock to occur no later than December 31, 2019, only, each share of Series D Preferred Stock held by a Holder, as such, shall be entitled to the whole number of votes equal to 30,001 shares of Common Stock. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the certificate of incorporation, holders of the Preferred Stock shall vote together with the holders of Common Stock as a single class. Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original Issue Date at the option of the Holder thereof, into that number of shares of Common Stock (subject to the limitations set forth in Section 6(d)) determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price. The Conversion Price is $0.005 per share. In December 2015, we issued 1,853 shares of our Series A 0% Convertible Preferred Stock, with a stated value of $1,000 per share and the common shares are issuable pursuant to conversion of the preferred stock at a conversion price of $4.50 per share, subject to a 9.99% beneficial ownership limitation and subject to adjustment pursuant to stock splits and dividends, and subject to adjustment pursuant to anti-dilution protection for subsequent equity sales for a period of 18 months from the effective date of the registration statement. In December 2016, we issued 1,000 shares of our Series B 0% Convertible Preferred Stock, with a stated value of $1,000 per share and the common shares are issuable pursuant to conversion of the preferred stock at a conversion price of $0.75 per share, subject to beneficial ownership limitations and subject to adjustment pursuant to stock splits and dividends, and subject to adjustment pursuant to anti-dilution protection for subsequent equity sales and other conversion price adjustments. In March and April, 2017, we sold 290.43148 shares of Series C 0% Convertible Preferred Stock. The Series C Preferred Stock has a stated value of $1,000 and is immediately convertible into 387,251 shares of the Company's common stock, subject to certain beneficial ownership limitations, at a conversion price equal to $0.75, subject to adjustment. The Conversion Price is subject to certain reset adjustments including the date of any future amendment to the Company's certificate of incorporation with respect to a reverse stock split. The Series C Preferred Stock has anti-dilution protection until such the twelve (12) month anniversary of the issuance of the Series C Preferred Stock. On September 12, 2017 we entered into an exchange agreement ("Exchange Agreement") with certain holders (the "Investors") of our Series A 0% Convertible Preferred Stock ("Series A Shares") and Series B 0% Convertible Preferred Stock ("Series B Shares"). Pursuant to the terms of the Exchange Agreement, we issued to the investors approximately $2.5 million in principal amount of senior convertible debentures in exchange for 1,614.8125 Series A Shares with a stated value of approximately $1.6 million and 890 Series B Shares with a stated value of approximately $0.9 million (collectively, the "Exchange"). In connection with the Exchange, such Series A Shares and Series B Shares have been cancelled and terminated. During 2017, 79.5 shares of Series A Preferred Stock and 39 shares of Series B Preferred Stock were converted into a total of 223,585 shares of common stock. As of December 31, 2018 and 2017, there were outstanding 133.81245 shares of Series A Preferred Stock, 71 shares of Series B Preferred Stock, and 290.43148 shares of Series C Preferred Stock. As a result of recent equity financings and conversions of debentures, the conversion prices of our Series A Preferred Stock has been reduced to $0.53 per share at December 31, 2018, the conversion price of 200 shares of our Series C preferred stock has been reduced to $0.02 per share at December 31, 2018, and our Series B Preferred Stock and 90.43418 shares of our Series C preferred stock has been reduced to $0.01 per share at December 31, 2018. Equity Financings March 2017 Offering In March, 2017, we sold $200,000 of the Company's securities consisting of 200 shares of Series C 0% Convertible Preferred Stock and an aggregate of 800,019 common stock purchase warrants as described below. The Series C Preferred Stock has a stated value of $1,000 and is immediately convertible into 266,673 shares of the Company's common stock, subject to certain beneficial ownership limitations, at a conversion price equal to $0.75, subject to adjustment. The Conversion Price is subject to certain reset adjustments including the date of any future amendment to the Company's certificate of incorporation with respect to a reverse stock split. The Series C Preferred Stock has anti-dilution protection until the twelve month anniversary of the issuance of the Series C Preferred Stock. The Investors also received an aggregate of approximately: (i) 266,673 Series M common stock purchase warrants ("Series M Warrants"), (ii) 266,673 Series N common stock purchase warrants ("Series N Warrants") and (iii) 266,673 Series O common stock purchase warrants ("Series O Warrants") (collectively, the "Warrants"). The Series M Warrants have an exercise price of $0.90 per share, subject to adjustment, and a term of five (5) years from the date of issuance, the Series N Warrants have an exercise price of $0.75 per share, subject to adjustment, and a term of six (6) months from the date of issuance and the Series O warrants have an exercise price of $0.75, subject to adjustment, and a term of twelve (12) months from the date of issuance. The Warrants are immediately exercisable and separately transferable from the Series C Preferred Stock. In the event that the shares underlying the Warrants are not subject to a registration statement at the time of exercise, the Warrants may be exercised on a cashless basis after 6 months from the issuance date. The Warrants also contain provisions providing for an adjustment in the underlying number of shares and exercise price in the event of stock splits or dividends and fundamental transactions. Additionally, the Warrants contain anti-dilution protection until the twelve (12) month anniversary of the issuance date. April 2017 Offering In April, 2017, we sold $90,431 of the Company's securities consisting of 90.43148 shares of Series C 0% Convertible Preferred Stock and an aggregate of 361,734 common stock purchase warrants as described below. The Series C Preferred Stock has a stated value of $1,000 and is immediately convertible into 120,578 shares of the Company's common stock, subject to certain beneficial ownership limitations, at a conversion price equal to $0.75, subject to adjustment. The Conversion Price is subject to certain reset adjustments including the date of any future amendment to the Company's certificate of incorporation with respect to a reverse stock split. The Series C Preferred Stock has anti-dilution protection until the twelve month anniversary of the issuance of the Series C Preferred Stock. The Investors also received an aggregate of approximately: (i) 120,578 Series M common stock purchase warrants ("Series M Warrants"), (ii) 120,578 Series N common stock purchase warrants ("Series N Warrants") and (iii) 120,578 Series O common stock purchase warrants ("Series O Warrants") (collectively, the "Warrants"). The Series M Warrants have an exercise price of $0.90 per share, subject to adjustment, and a term of five (5) years from the date of issuance, the Series N Warrants have an exercise price of $0.75 per share, subject to adjustment, and a term of six (6) months from the date of issuance and the Series O warrants have an exercise price of $0.75, subject to adjustment, and a term of twelve (12) months from the date of issuance. The Warrants are immediately exercisable and separately transferable from the Series C Preferred Stock. In the event that the shares underlying the Warrants are not subject to a registration statement at the time of exercise, the Warrants may be exercised on a cashless basis after 6 months from the issuance date. The Warrants also contain provisions providing for an adjustment in the underlying number of shares and exercise price in the event of stock splits or dividends and fundamental transactions. Additionally, the Warrants contain anti-dilution protection until the twelve (12) month anniversary of the issuance date. Conversion and exercise price resets As a result of recent equity financings and conversions of debentures, the conversion prices of our Series A Preferred Stock has been reduced to $0.53 per share at December 31, 2018, the conversion price of 200 shares of our Series C preferred stock has been reduced to $0.02 per share at December 31, 2018, and our Series B Preferred Stock and 90.43148 shares of our Series C preferred stock has been reduced to $0.01 per share at December 31, 2018. The exercise prices of the warrants issued in conjunction with the Series B and Series C preferred stock have also been reduced to $0.02 and $0.01 per share, respectively, at December 31, 2018. As a result of the reductions of the conversion prices of our preferred stock and warrants, we have recorded deemed dividends of approximately $196,000 and $2,204,000 during the years ended December 31, 2018 and 2017, respectively. Common Stock During the year ended December 31, 2018, we issued a total of 73,675,000 shares of common stock, valued at $503,308, upon the conversion of $361,255 principal amount of our convertible debentures. During 2017, we issued a total of 223,585 shares of common stock upon the conversion of 79.5 shares of Series A Preferred Stock and 39 shares of Series B Preferred Stock. During 2017, we issued a total of 2,144,340 shares of common stock, valued at $155,153, upon the conversion of $122,370 principal amount of our convertible debentures. Effective July 31, 2017 we issued 7,122,172 shares of common stock to acquire 100% of the capital stock of Lewis & Clark, Pharmaceuticals, Inc., a Virginia Corporation, pursuant to the terms of a share exchange agreement dated July 31, 2017.

Stock Options

Stock Options	12 Months Ended
	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
STOCK OPTIONS	NOTE 10 – STOCK OPTIONS Deferred Compensation Plan In July of 2011, we adopted Executive Deferred Compensation Plan (the Deferred Plan). The Deferred Plan is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the Code). The Deferred Plan is intended to be an unfunded "top hat" plan which is maintained primarily to provide deferred compensation benefits for a select group of our "management or highly compensated employees" within the meaning of Sections 201, 301, and 401 of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and to therefore be exempt from the provisions of Parts 2, 3, and 4 of Title I of ERISA. The Deferred Plan is intended to help build a supplemental source of savings and retirement income through pre-tax deferrals of eligible compensation, which may include cash, option and stock bonus awards, discretionary cash, option and stock awards and/or any other payments which may be designated by the Deferred Plan administrator, as eligible, for deferral under the Deferred Plan from time to time. As administered, the Deferred Plan is used to defer compensation of stock awards granted under our other equity compensation plans and does not by its terms approve any grants or awards. Inspyr's Compensation Plans The Company's 2007 Equity Compensation Plan (2007 Plan), 2009 Executive Compensation Plan (2009 Plan), 2017 Equity Compensation Plan (2017 Plan), and the Inducement Award Stock Option Plan (Inducement Plan) (together, the Plans) provide for the awarding of stock grants, nonqualified and incentive stock options, restricted stock units, performance units or other stock-based awards to officers, directors, employees and consultants of the Company. The purpose of the Plans is to advance the interests of Inspyr and our stockholders by attracting, retaining and rewarding persons performing services for us and to motivate such persons to contribute to our growth and profitability. Our Plans are administered by a committee of non-employee directors (the Committee). The Committee determines: who shall be granted awards; the vesting periods; the exercise price; and any other terms deemed appropriate for any award. Our 2007 Plan is administered by our board or any of its committees. The purposes of the 2007 Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants, and to promote the success of our business. The issuance of awards under our 2007 Plan is at the discretion of the administrator, which has the authority to determine the persons to whom any awards shall be granted and the terms, conditions and restrictions applicable to any award. Under our 2007 Plan, we may grant stock options, restricted stock, stock appreciation rights, restricted stock units, performance units, performance shares and other stock based awards. Our 2007 Plan authorizes the issuance of up to 50,000 shares of common stock for the foregoing awards per fiscal year with an aggregate of 200,000 shares of common stock available for issuance under the 2007 Plan. As of December 31, 2018, we have granted awards under the 2007 Plan equal to approximately 180,699 shares of our common stock, and 111,963 shares have been cancelled or forfeited. Accordingly, there are 131,264 shares of common stock available for future awards under the 2007 Plan. In the event of a change in control, awards under the 2007 Plan will become fully vested unless such awards are assumed or substituted by the successor corporation. Our 2009 Plan, as amended is administered by our Board or any of its committees. The purpose of our 2009 Plan is to advance the interests of the Company and our stockholders by attracting, retaining and rewarding persons performing services for us and to motivate such persons to contribute to our growth and profitability. The issuance of awards under our 2009 Plan is at the discretion of the administrator, which has the authority to determine the persons to whom any awards shall be granted and the terms, conditions and restrictions applicable to any award. Under our 2009 Plan, we may grant stock options, restricted stock, stock appreciation rights, restricted stock units, performance units, performance shares and other stock-based awards. As of December 31, 2018, our 2009 Plan authorizes the issuance of up to 200,000 shares of our common stock for the foregoing awards, and we have granted awards under the plan equal to approximately 164,868 common shares, and 115,782 shares have been cancelled or forfeited. Accordingly, there are 150,914 shares of common stock available for future awards under the 2009 Plan. Our Inducement Plan is administered by our board or our compensation committee. The Plan is intended to be used in connection with the recruiting and inducement of senior management and employees. The issuance of wards under the Inducement Plan is at the discretion of the administrator which has the authority to determine the persons to whom any awards shall be granted and the terms, conditions and restrictions applicable to any award. The Company did not seek approval of the Plan by our stockholders. Pursuant to the Inducement Plan, the Company may grant stock options for up to a total of 300,000 shares of common stock to new employees of the Company. As of December 31, 2018, 211,360 grants have been made pursuant to the Plan. Our 2017 Plan is administered by our Board or any of its committees. The purpose of our 2017 Plan is to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to employees, directors and consultants, and to promote the success of the Company's business. The issuance of awards under our 2017 Plan is at the discretion of the administrator, which has the authority to determine the persons to whom any awards shall be granted and the terms, conditions and restrictions applicable to any award. Under our 2017 Plan, we may grant stock options, restricted stock, stock appreciation rights, restricted stock units, performance units, performance shares and other stock-based awards. As of December 31, 2018, our 2017 Plan authorizes the issuance of up to 2,000,000 shares of our common stock for the foregoing awards, and we have not granted any awards under the plan. Accordingly, there are 2,000,000 shares of common stock available for future awards under the 2017 Plan. The Company has recorded aggregate stock-based compensation expense related to the issuance of stock option awards in the following line items in the accompanying consolidated statement of losses (in thousands): Years Ended December 31, 2018 2017 Research and development $ 62 $ 127 General and administrative 28 75 Total stock-based compensation expense $ 90 $ 202 During the year ended December 31, 2018, we accelerated the vesting of all unvested employee options. As of December 31, 2018, there was no unrecognized compensation cost related to non-vested stock options. The following table summarizes stock option activity for the years ended December 31, 2018 and 2017: Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2016 268,876 $ 24.1504 Granted 104,747 $ 0.54 Forfeited (17,343 ) $ 41.54 Outstanding at December 31, 2017 356,280 $ 7.45 4.4 $ — Granted — $ — Forfeited (32,766 ) $ 18.99 Outstanding at December 31, 2018 323,514 $ 6.28 3.8 $ — Exercisable at December 31, 2018 323,514 $ 6.28 3.8 $ — During 2017, the Company issued options to purchase 104,747 shares of common stock to employees, and non-employee directors under the Plans. The weighted-average fair value of the options granted to employees and non-employee directors during 2017 was estimated at $0.59 per share on the date of grant. The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued for the year ended December 31, 2017: 2017 Volatility 128.5 % Expected term (years) 3.2 Risk-free interest rate 1.41 % Dividend yield None No options were exercised during the years ended December 31, 2018 and 2017.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2018
Warrants
WARRANTS	NOTE 11 – WARRANTS On February 28, 2017, Russell Richerson, PhD, resigned as chief operating officer of the Company, effective immediately. Dr. Richerson entered into a separation release of claims agreement ("Separation Agreement") pursuant to which we issued Dr. Richerson a warrant to purchase 76,726 shares of Common Stock with an exercise price of $0.75 per share and a term of 3.5 years. In connection with the sale of our Series C Preferred Stock in March and April 2017, we issued an aggregate of: (i) 387,251 Series M common stock purchase warrants ("Series M Warrants"), (ii) 387,251Series N common stock purchase warrants ("Series N Warrants") and (iii) 387,251 Series O common stock purchase warrants ("Series O Warrants") (collectively, the "Warrants"). The Series M Warrants have an exercise price of $0.90 per share, subject to adjustment, and a term of five (5) years from the date of issuance, the Series N Warrants have an exercise price of $0.75 per share, subject to adjustment, and a term of six (6) months from the date of issuance and the Series O warrants have an exercise price of $0.75, subject to adjustment, and a term of twelve (12) months from the date of issuance. The Warrants are immediately exercisable and separately transferable from the Series C Preferred Stock. In the event that the shares underlying the Warrants are not subject to a registration statement at the time of exercise, the Warrants may be exercised on a cashless basis after 6 months from the issuance date. The Warrants also contain provisions providing for an adjustment in the underlying number of shares and exercise price in the event of stock splits or dividends and fundamental transactions. Additionally, the Warrants contain anti-dilution protection until the twelve (12) month anniversary of the issuance date. Transactions involving our warrants are summarized as follows: Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2016 5,203,436 $ 4.56 Granted 1,238,479 $ 0.08 Forfeited (3,396,175 ) $ 1.43 Outstanding at December 31, 2017 3,045,740 $ 5.39 3.1 $ - Granted — $ — Forfeited (532,810 ) $ 15.87 Outstanding at December 31, 2018 2,512,930 $ 3.16 2.7 $ - Exercisable at December 31, 2018 2,512,930 $ 3.16 2.7 $ - No warrants were exercised during the years ended December 31, 2018 and 2017. As a result of recent equity financings and conversions of debentures, the exercise prices of the warrants issued in conjunction with our Series B and Series C preferred stock have also been reduced to $0.02 and $0.01 per share, respectively, at December 31, 2018. The following table summarizes outstanding common stock purchase warrants as of December 31, 2018: Number of Weighted- Expiration Issued to consultants 102,213 $ 7.09 February 2019 through August 2023 Issued pursuant to 2014 financings 96,412 $ 34.50 June 2019 Issued pursuant to 2015 financings 460,384 $ 8.40 July 2020 through December 2020 Issued pursuant to 2016 financings 1,466,670 $ 0.01 December 2021 Issued pursuant to 2017 financings 387,251 $ 0.02 March 2022 through April 2022 2,512,930

Convertible Debentures and Note

Convertible Debentures and Notes	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
CONVERTIBLE DEBENTURES AND NOTES	NOTE 12 – CONVERTIBLE DEBENTURES AND NOTES On December 13, 2018 we issued an aggregate of $25,000 in convertible promissory notes ("Notes") for cash proceeds of $25,000. The Notes will mature on the earlier of (i) June 30, 2019 or (ii) such time as we raise capital in exchange for the sale of securities ("Maturity Date") and bear interest at 10% per year, payable on the Maturity Date. Pursuant to the terms of the Notes, the Notes may be converted into shares of common stock upon an Event of Default (as such term is defined in the Notes) or upon the Maturity Date at the election of the holder at a price per share equal to 75% of the lowest trade price of our common stock on the trading day immediately prior to the date such exchange is exercised by the holder. On July 3, 2018, we entered into securities purchase agreements ("Securities Purchase Agreement") with certain institutional investors (the "Investors"). Pursuant to the Securities Purchase Agreement, we sold an aggregate of $515,000 of senior convertible debentures ("Debentures") consisting of $500,000 in cash and the cancellation of $15,000 of obligations of the Company (the "Offering"). Pursuant to the terms of the Securities Purchase Agreement, we will issue $515,000 in principal amount of Debentures. The Debentures (i) are non-interest bearing, (ii) have a maturity date one (1) year from the date of issuance and (iii) are convertible into shares of our common stock at the election of the Investor at any time, subject to a beneficial ownership limitation of 4.99% which may be increased to 9.99% by the Investor upon 61 days' notice. The Debentures will have a conversion price equal to the lesser of (i) $0.33 and (ii) 85% of the lesser of (a) the volume weighted average price on the trading day immediately preceding a conversion date and (b) the volume weighted average price on a conversion date. The Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The Investors will also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the Debentures. The maturity date of the debentures has been extended to September 30, 2019 (see Note 15). Furthermore, without the approval of the Investors holding at least 67% of the then outstanding principal amount of the Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any Investor, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company. The Company is also required under the Securities Purchase Agreement to hold a shareholder meeting by January 3, 2019 in order to increase the number of authorized shares of Common Stock of the Company such that there are sufficient shares of Common Stock available for issuance underlying the Debentures upon their conversion in full. The Company is also obligated under the Securities Purchase Agreement to pay Investors, as partial liquidated damages, a fee of 2.0% of each Investor's initial principal amount of such Investor's Debenture in cash upon our failure to have current public information available beginning six (6) months after the issuance date of the Debentures. The Investors were additionally given a right of participation in future offerings for a period of up to eighteen (18) months from the date on which the shares underlying the Debentures are registered. The Securities Purchase Agreement also prohibits us from issuing any common stock, subject to certain exemptions, for a period of 60 days following the closing of the Offering, without the written approval of the Investors owning at least 50.1% of the securities issued in the Offering. Additionally, until the twelve month anniversary of the registration of the shares underlying the Debentures, we are prohibited from entering into any agreement to effect any issuance of common stock in a variable rate transaction. On September 12, 2017 we entered into an exchange agreement ("Exchange Agreement") with certain holders (the "Investors") of our Series A 0% Convertible Preferred Stock ("Series A Shares") and Series B 0% Convertible Preferred Stock ("Series B Shares"). Pursuant to the terms of the Exchange Agreement, we issued to the investors approximately $2.5 million in principal amount of senior convertible debentures ("Debentures") in exchange for 1,614.8125 Series A Shares with a stated value of approximately $1.6 million and 890 Series B Shares with a stated value of approximately $0.9 million. On September 12, 2017, we sold an aggregate of $320,000 of our Debentures. The sale consisted of $250,000 in cash and the cancellation of $70,000 of obligations of the Company. The Debentures to be issued to the Investors (i) are non-interest bearing, (ii) have a maturity date of September 12, 2018 and (iii) are convertible into shares of common stock ("Common Stock") of the Company at the election of the Investor at any time, subject to a beneficial ownership limitation of 4.99% which may be increased to 9.99% by the Investor upon 61 days' notice. The Debentures will have a conversion price equal to the lesser of (i) $0.33 and (ii) 85% of the lesser of (a) the volume weighted average price on the trading day immediately preceding a conversion date and (b) the volume weighted average price on a conversion date. The maturity date of the debentures has been extended to September 30, 2019 (see Note 15). The Debentures also contain provisions providing for an adjustment in the event of stock splits or dividends, and fundamental transactions. The Investors will also have the right to participate in subsequent rights offerings and pro rata distributions. Additionally, the Debentures contain anti-dilution protection in the event of subsequent equity sales at a price that is lower than the then applicable conversion price until such time that the Debentures are no longer outstanding. Additionally, the Company has the option to redeem some or all of the Debentures for cash upon notice of twenty (20) trading days provided certain conditions are met by the Company as more fully described in the Debentures. Furthermore, without the approval of the Investors holding at least 67% of the then outstanding principal amount of the Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any Investor, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company. The Company is also obligated pay Investors, as partial liquidated damages, a fee of 2.0% of each Investor's initial principal amount of such Investor's Debenture in cash upon our failure to have current public information available. This requirement has been waived by the Investors through September 30, 2019 (see Note 15). In connection with the Offering, the Investors also entered in a registration rights agreement ("Registration Rights Agreement"). Pursuant to the Registration Rights Agreement, the Company agreed to file a registration statement with the Securities and Exchange Commission ("the Commission") within 45 days from the date of the Registration Rights Agreement to register the resale of 100% of the shares of Common Stock underlying the Debentures and to maintain the effectiveness thereunder. The Company also agreed to have the registration statement declared effective within 75 days from the date of the Registration Rights Agreement and keep the registration statement continuously effective until the earlier of (i) the date after which all of the securities to be registered thereunder have been sold, or (ii) the date on which all the securities to be registered thereunder may be sold without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 under the Securities Act of 1933, as amended. We are also obligated to pay the Investors, as partial liquidated damages, a fee of 1.5% of each Investor's subscription amount per month in cash upon the occurrence of certain events, including our failure to file and / or have the registration statement declared effective within the time periods provided. This requirement has been waived by the Investors through September 30, 2019 (see Note 15). The Investors were additionally given a right of participation in future offerings for a period of up to eighteen months from the date in which the shares underlying the Debentures are registered as contemplated in the Registration Rights Agreement. The Securities Purchase Agreement also prohibits the Company from issuing any Common Stock, subject to certain exemptions, for a period of 60 days following the closing of the Offering, without the written approval of the Investors owning at least 50.1% of the securities issued in the Offering. Additionally, until the twelve (12) month anniversary of such effectiveness of the registration statement as contemplated in the Registration Rights Agreement, the Company is prohibited from entering into any agreement to effect any issuance of Common Stock in a variable rate transaction.

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
ACQUISITION	NOTE 13 – ACQUISITION On July 31, 2017, we acquired 100% of the capital stock of Lewis & Clark, Pharmaceuticals, Inc., a Virginia Corporation ("L&C"), pursuant to the terms of a share exchange agreement ("Agreement") dated July 31, 2017 ("Closing Date"), by and among, the Company, L&C, certain principals of L&C (the "Principals") and all of the existing shareholders of L&C ("Shareholders"). As consideration for the acquisition of L&C, the Company agreed to issue an aggregate of 7,122,172 shares of the Company's common stock ("Payment Shares") to the Shareholders, accounting for, subsequent to the closing of the transaction, the Shareholders owning 50% of the issue and outstanding capital stock of the Company (including common shares issuable upon conversion of the Company's outstanding preferred stock). The shares issued for the acquisition of L&C have been valued at $2,492,760. The Principals have agreed to establish escrow accounts with respect to an aggregate of 973,251 of the Payment Shares pursuant to a share escrow agreement ("Escrow Agreement") in order to satisfy certain indemnification obligations to the extent such may arise under the Agreement for the benefit of the Company, its shareholders, and its personnel. The Agreement contains certain customary indemnification provisions with respect to the Company one on hand and L&C and the Principals, on the other hand. Additionally, pursuant to the Agreement, all Shareholders that receive at least 5% of the Payment Shares (at least 356,109 shares) (including any shares held in escrow) agree to vote such shares in accordance with the recommendation of the Company's board of directors ("Board") with respect to any matter to be voted upon by shareholders of the Company for a period of eighteen (18) months from the Closing Date. Furthermore, each Shareholder agrees that for a period of eighteen (18) months from the Closing Date, it will not sell or transfer any of the Payment Shares it receives pursuant to the Agreement, except that if a Shareholder is employed by the Company, it may sell up to five percent (5%) of Payment Shares it receives on each ninety (90) day period following the one (1) year anniversary of the Closing Date. The allocation of the purchase price to the assets acquired and liabilities assumed based on the estimated fair values is as follows (in thousands): Cash $ 23 Prepaid expenses 3 Equipment 353 Goodwill 2,159 Total assets acquired 2,538 Accounts payable and other liabilities (45 ) Total $ 2,493 Due to the suspension of business activity in February 2018, the Company determined that the goodwill assigned to the Lewis & Clark, Pharmaceuticals, Inc. acquisition had become fully impaired as of December 31, 2017. Accordingly, we recorded a goodwill impairment charge of $2.2 million during the year ended December 31, 2017. The Company also determined that the office and lab equipment acquired pursuant to the Lewis & Clark, Pharmaceuticals, Inc. acquisition had become fully impaired as of December 31, 2017. Accordingly, we recorded an impairment charge of $0.3 million during the year ended December 31, 2017. Pro forma results The following tables set forth the unaudited pro forma results of the Company as if the acquisition of L&C had taken place on the first day of the periods presented. These combined results are not necessarily indicative of the results that may have been achieved had the companies been combined as of January 1, 2017, the first day of the periods presented. 2017 Revenue $ — Net loss attributable to common shareholders (13,842 ) Net loss per share (1.54 ) The amounts of revenue and loss of L&C since the acquisition date included in the consolidated statement of operations for the year ended December 31, 2017 are approximately $0 and ($2,813,000), respectively, including goodwill impairment of approximately $2,159,000.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 14 — INCOME TAXES On December 22, 2017, the Tax Cuts and Jobs Act (the "Act"), a tax reform bill, was enacted. The Act, among other items, reduces the current federal income tax rate to 21% from 35%. The rate reduction is effective January 1, 2018, and is permanent. The Act has caused the Company's deferred income taxes to be revalued. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through income tax expense. Pursuant to the guidance within SEC Staff Accounting Bulletin No. 118 ("SAB 118"), as of December 31, 2017, the Company recognized the provisional effects of the enactment of the Act for which measurement could be reasonably estimated. Since the Company has provided a full valuation allowance against its deferred tax assets, the revaluation of the deferred tax assets did not have a material impact on any period presented. The ultimate impact of the Act may differ from these estimates due to the Company's continued analysis or further regulatory guidance that may be issued as a result of the Act. As a result of the reduction of the federal corporate income tax rate, the Company reduced the value of its net deferred tax asset by approximately $6.1 million which was recorded as a corresponding reduction to the valuation allowance during the fourth quarter of 2017. The Company had, subject to limitation, $40.3 million of net operating loss carryforwards at December 31, 2018, which will expire at various dates through 2037. In addition, the Company has research and development tax credits of approximately $458,000 at December 31, 2018 available to offset future taxable income, which will expire from 2028 through 2037. We have provided a 100% valuation allowance for the deferred tax benefits resulting from the net operating loss carryover and our tax credits due to our lack of earnings history. In addressing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. The valuation allowance increased by approximately $178,000 and $832,000 for the years ended December 31, 2018 and 2017, respectively. Significant components of deferred tax assets and liabilities are as follows (in thousands): 2018 2017 Deferred tax assets: Net operating loss carryover $ 8,597 $ 8,468 Stock-based compensation 1,920 1,920 Accrued compensation 334 288 Other 30 27 Tax credits 458 458 Total deferred tax assets 11,339 11,161 Less: valuation allowance (11,339 ) (11,161 ) Net deferred tax assets $ — $ — The actual tax benefit differs from the expected tax benefit for the years ended December 31, 2018 and 2017 (computed by applying the U.S. Federal Corporate tax rate of 34% to income before taxes) are as follows: 2018 2017 Statutory federal income tax rate (21.0 )% (34.0 )% State income taxes, net of federal benefits (7.0 )% (5.8 )% Non-deductible items (1,418.0 )% 28.5 % Valuation allowance 1,446.0 % 11.3 % Effective income tax rate — % — % The Company's tax returns for the previous three years remain open for audit by the respective tax jurisdictions.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 15 – SUBSEQUENT EVENTS During January 2019, we issued a total of 65,436,071 shares of common stock upon the conversion of $204,221 principal amount of our convertible debentures. During January 2019, we issued 5,000 shares of Series D Convertible Preferred Stock for proceeds of $5,000. Effective July 5, 2019, Sabby Healthcare Master Fund, Ltd and Sabby Volatility Warrant Master Fund, Ltd. waived certain events of default under debentures issued in our July 2018 debenture offering and September 2017 debenture offering (collectively, the "Debenture Offerings") and extended the maturity date of such debentures until September 30, 2019 in exchange for the issuance of $154,000 in new debentures with substantially the same terms as those issued in our Debenture Offerings. On July 15, 2019, Christopher Lowe resigned as our chief executive officer, chief financial officer, president, and as a member of the Board. On July 26, 2019, we appointed Michael Cain as our interim chief executive officer, chief financial officer, president, and as a member of the Board.

Summary of Critical Accountin_2

Summary of Critical Accounting Policies and Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Significant estimates include the fair value of derivative instruments, stock-based compensation, recognition of clinical trial costs and other accrued liabilities. Actual results may differ from those estimates.
Research and Development	Research and Development Research and development costs are charged to expense as incurred. Our research and development expenses consist primarily of expenditures for toxicology and other studies, manufacturing, clinical trials, compensation and consulting costs. We incurred research and development expenses of $0.2 million and $1.7 million for the years ended December 31, 2018 and 2017, respectively.
Cash Equivalents	Cash Equivalents For purposes of the statements of cash flows, we consider all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts which, at times, may exceed applicable government mandate insurance limits. We have not experienced any losses in our accounts. We did not have any cash equivalents at December 31, 2018 or 2017.
Restricted Cash	Restricted Cash Restricted cash consists of funds held in trust for the Company. The use of these funds is restricted to: (i) the payment of professional fees in connection with bringing the Company's filings current, and (ii) the payment of vendors associated with the issuance and trading of the Company's securities, such as transfer agent fees and fees payable to the OTCQB and FINRA.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such investments may exceed applicable government mandated insurance limits. Cash and restricted cash was $0.3 million and $0.01 million at December 31, 2018 and 2017, respectively. As of December 31, 2018 and 2017, there was no cash over the federally insured limit.
Intangible Assets	Intangible Assets Intangible assets consist of licensed technology, patents, and patent applications (see Note 5). The assets associated with licensed technology are recorded at cost and are being amortized on the straight line basis over their estimated useful lives of twelve to seventeen years.
Office and Lab Equipment	Office and Lab Equipment Equipment is stated at cost less accumulated depreciation. Depreciation is calculated on the straight line basis over the estimated useful lives of the assets of three to seven years. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to expense. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its equipment for impairment. Due to the suspension of business activity in February 2018, the Company determined that the office and lab equipment acquired pursuant to the Lewis & Clark, Pharmaceuticals, Inc. acquisition had become fully impaired as of December 31, 2017. Accordingly, we recorded an impairment charge of $0.3 million during the year ended December 31, 2017. Depreciation expense was approximately $2,000 and $23,000 for the years ended December 31, 2018 and 2017, respectively.
Loss per Share	Loss per Share Basic loss per share is calculated by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding for the period. Basic and diluted loss per share are the same, in that any potential common stock equivalents would have the effect of being anti-dilutive in the computation of net loss per share. The following potentially dilutive securities have been excluded from the computations of weighted average shares outstanding as of December 31, 2018 and 2017, as they would be anti-dilutive: Year Ended December 31, 2018 2017 Shares underlying options outstanding 323,514 356,280 Shares underlying warrants outstanding 2,512,930 3,045,740 Shares underlying convertible notes outstanding 828,337,812 135,122,128 Shares underlying convertible preferred stock outstanding 26,395,624 18,324,050 857,569,880 156,848,198
Derivative Liability	Derivative Liability The Company has financial instruments that are considered derivatives or contain embedded features subject to derivative accounting. Embedded derivatives are valued separately from the host instrument and are recognized as derivative liabilities in the Company's balance sheet. The Company measures these instruments at their estimated fair value and recognizes changes in their estimated fair value in results of operations during the period of change. The Company values its derivative liabilities using the Black-Scholes option valuation model. The resulting liability is valued at each reporting date and the change in the liability is reflected as change in derivative liability in the statement of operations.
Goodwill	Goodwill Our goodwill consists of the excess purchase price paid in business combinations over the fair value of assets acquired. Goodwill is considered to have an indefinite life. The Company has decided to perform its annual goodwill and impairment assessment on December 31st of each year. The Company employs the non-amortization approach to account for goodwill. Under the non-amortization approach, goodwill is not amortized into the results of operations, but instead is reviewed annually or more frequently if events or changes in circumstances indicate that the asset might be impaired, to assess whether the fair value exceeds the carrying value. When evaluating the potential impairment of goodwill, we first assess a range of qualitative factors, including but not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for the Company's products and services, regulatory and political developments, entity specific factors such as strategy and changes in key personnel, and the overall financial performance for each of the Company's reporting units. If, after completing this assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then proceed to a two-step impairment testing methodology using the income approach (discounted cash flow method). In the first step of the two-step testing methodology, we compare the carrying value of the reporting unit, including goodwill, with its fair value, as determined by its estimated discounted cash flows. If the carrying value of a reporting unit exceeds its fair value, we then complete the second step of the impairment test to determine the amount of impairment to be recognized. In the second step, we estimate an implied fair value of the reporting unit's goodwill by allocating the fair value of the reporting unit to 100% of the assets and liabilities other than goodwill (including any unrecognized intangible assets). If the carrying value of a reporting unit's goodwill exceeds its implied fair value, the Company records an impairment loss equal to the difference in that period. When required, we arrive at our estimates of fair value using a discounted cash flow methodology which includes estimates of future cash flows to be generated by specifically identified assets, as well as selecting a discount rate to measure the present value of those anticipated cash flows. Estimating future cash flows requires significant judgment and includes making assumptions about projected growth rates, industry-specific factors, working capital requirements, weighted average cost of capital, and current and anticipated operating conditions. The use of different assumptions or estimates for future cash flows could produce different results. Due to the suspension of business activity in February 2018, the Company determined that the goodwill assigned to the Lewis & Clark, Pharmaceuticals, Inc. acquisition had become fully impaired as of December 31, 2017. Accordingly, we recorded a goodwill impairment charge of $2.2 million during the year ended December 31, 2017.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Our short-term financial instruments, including cash, accounts payable and other liabilities, consist primarily of instruments with maturities of three months or less when acquired. We believe that the fair values of our current assets and current liabilities approximate their reported carrying amounts. The derivative liability consists of our convertible notes with a variable conversion feature. The Company uses the Black-Scholes option-pricing model to value its derivative liability which incorporate the Company's stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.
Fair Value Measurements	Fair Value Measurements The U.S. GAAP Valuation Hierarchy establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability's classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company has recorded a derivative liability for its convertible notes with a variable conversion feature as of December 31, 2018. The tables below summarize the fair values of our financial liabilities as of December 31, 2018 (in thousands): Fair Value at Fair Value Measurement Using 2018 Level 1 Level 2 Level 3 Derivative liability $ 2,134 $ — $ — $ 2,134 The reconciliation of the derivative liability measured at fair value on a recurring basis using unobservable inputs (Level 3) is as follows (in thousands): Year ended December 31, 2018 2017 Balance at beginning of year $ 2,934 $ — Additions to derivative instruments 604 2,952 Reclassification on conversion (352 ) (121 ) Loss (gain) on change in fair value of derivative liability (1,052 ) 103 Balance at end of period $ 2,134 $ 2,934
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which the related temporary difference becomes deductible.
Stock-Based Compensation	Stock-Based Compensation We measure the cost of employee services received in exchange for equity awards based on the grant-date fair value of the awards. All awards under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to non-employees is determined in accordance with the fair value of the consideration received or the fair value of the equity instruments issued, whichever is a more reliable measurement. Compensation expense for awards granted to non-employees is re-measured on each accounting period. Determining the appropriate fair value of stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based compensation and the volatility of our stock price. We use the Black-Scholes option-pricing model to value our stock option awards which incorporates our stock price, volatility, U.S. risk-free interest rate, dividend rate, and estimated life.
Effect of ASU No. 2017-11 on Previously Issued Financial Statements	Effect of ASU No. 2017-11 on Previously Issued Financial Statements In July 2017, the Financial Accounting Standards Board ("FASB") issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): Part 1 – Accounting for Certain Financial Instruments with Down Round Features and Part 2 – Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with Scope Exception ("ASU No. 2017-11"). Part 1 of ASU No. 2017-11 addresses the complexity of accounting for certain financial instruments with down round features. Down round features are provisions in certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require fair value measurement of the entire instrument or conversion option. Part II of ASU No. 2017-11 addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification®. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. For public business entities, the amendments in Part I of this update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company has early adopted the guidance under ASU 2017-11 for the year end December 31, 2017.
Recent Accounting Pronouncements	Recent Accounting Pronouncements With the exception of those discussed below, there have not been any recent changes in accounting pronouncements and Accounting Standards Update (ASU) issued by the Financial Accounting Standards Board (FASB) during the year ended December 31, 2018 that are of significance or potential significance to the Company. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company does not expect any impact from the adoption of this standard on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU No. 2017-04"). ASU No. 2017-04 simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. A public business entity that is a SEC filer should adopt the amendments of ASU No. 2017-04 for its annual and interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not expect any impact from the adoption of this standard on its consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, "Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting", which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. If an award is not probable of vesting at the time a change is made, the new guidance clarifies that no new measurement date will be required if there is no change to the fair value, vesting conditions, and classification. This ASU will be applied prospectively and is effective for fiscal years beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. The adoption of this standard did not have a material impact on its consolidated financial statements.

Summary of Critical Accountin_3

Summary of Critical Accounting Policies and Use of Estimates (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of weighted average shares outstanding	Year Ended December 31, 2018 2017 Shares underlying options outstanding 323,514 356,280 Shares underlying warrants outstanding 2,512,930 3,045,740 Shares underlying convertible notes outstanding 828,337,812 135,122,128 Shares underlying convertible preferred stock outstanding 26,395,624 18,324,050 857,569,880 156,848,198
Schedule of fair values of financial liabilities	Fair Value at Fair Value Measurement Using 2018 Level 1 Level 2 Level 3 Derivative liability $ 2,134 $ — $ — $ 2,134
Schedule of fair value of derivative liability on recurring basis	Year ended December 31, 2018 2017 Balance at beginning of year $ 2,934 $ — Additions to derivative instruments 604 2,952 Reclassification on conversion (352 ) (121 ) Loss (gain) on change in fair value of derivative liability (1,052 ) 103 Balance at end of period $ 2,134 $ 2,934

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	12 Months Ended
	Dec. 31, 2018
Supplemental Cash Flow Information [Abstract]
Schedule of additional information of cash flow	Year Ended December 31, 2018 2017 Non-cash financial activities: Common stock issued on conversion of notes payable and derivative liability $ 503 $ 155 Debentures converted to common stock 361 122 Derivative liability extinguished upon conversion of notes payable 352 121 Derivative liability issued 604 2,952 Net assets and liabilities recognized with the acquisition of Lewis and Clark Pharmaceuticals, Inc. — 2,493 Accounts payable paid through issuance of debentures 15 70 Debentures issued to retire preferred stock — 2,505 Preferred stock and warrants issued for fees — 5

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
Accrued Liabilities, Current [Abstract]
Schedule of accrued expenses	December 31, 2018 2017 Accrued compensation and benefits $ 1,326 $ 1,154 Accrued research and development 188 144 Accrued other 300 241 Total accrued expenses $ 1,814 $ 1,539

Derivative Liability (Tables)

Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of black scholes valuations of derivatives	2018 Volatility 204 % Expected term (years) 8 months Risk-free interest rate 2.59 % Dividend yield None

Stock Options (Tables)

Stock Options (Tables)	12 Months Ended
	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Schedule of stock-based compensation expense	Years Ended December 31, 2018 2017 Research and development $ 62 $ 127 General and administrative 28 75 Total stock-based compensation expense $ 90 $ 202
Schedule of stock option activity	Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2016 268,876 $ 24.1504 Granted 104,747 $ 0.54 Forfeited (17,343 ) $ 41.54 Outstanding at December 31, 2017 356,280 $ 7.45 4.4 $ — Granted — $ — Forfeited (32,766 ) $ 18.99 Outstanding at December 31, 2018 323,514 $ 6.28 3.8 $ — Exercisable at December 31, 2018 323,514 $ 6.28 3.8 $ —
Schedule of weighted-average assumptions	2017 Volatility 128.5 % Expected term (years) 3.2 Risk-free interest rate 1.41 % Dividend yield None

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2018
Warrants
Schedule of transactions involving of warrants	Number of Weighted- Weighted- Aggregate Outstanding at December 31, 2016 5,203,436 $ 4.56 Granted 1,238,479 $ 0.08 Forfeited (3,396,175 ) $ 1.43 Outstanding at December 31, 2017 3,045,740 $ 5.39 3.1 $ - Granted — $ — Forfeited (532,810 ) $ 15.87 Outstanding at December 31, 2018 2,512,930 $ 3.16 2.7 $ - Exercisable at December 31, 2018 2,512,930 $ 3.16 2.7 $ -
Schedule of outstanding warrants to purchase common stock	Number of Weighted- Expiration Issued to consultants 102,213 $ 7.09 February 2019 through August 2023 Issued pursuant to 2014 financings 96,412 $ 34.50 June 2019 Issued pursuant to 2015 financings 460,384 $ 8.40 July 2020 through December 2020 Issued pursuant to 2016 financings 1,466,670 $ 0.01 December 2021 Issued pursuant to 2017 financings 387,251 $ 0.02 March 2022 through April 2022 2,512,930

Acquisition (Tables)

Acquisition (Tables)	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Schedule of final accounting	Cash $ 23 Prepaid expenses 3 Equipment 353 Goodwill 2,159 Total assets acquired 2,538 Accounts payable and other liabilities (45 ) Total $ 2,493
Schedule of pro forma result of acquisition	2017 Revenue $ — Net loss attributable to common shareholders (13,842 ) Net loss per share (1.54 )

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Weighted-average exercise price [Roll Forward]
Schedule of deferred tax assets and liabilities	2018 2017 Deferred tax assets: Net operating loss carryover $ 8,597 $ 8,468 Stock-based compensation 1,920 1,920 Accrued compensation 334 288 Other 30 27 Tax credits 458 458 Total deferred tax assets 11,339 11,161 Less: valuation allowance (11,339 ) (11,161 ) Net deferred tax assets $ — $ —
Schedule of actual tax benefit differs from the expected tax benefit	2018 2017 Statutory federal income tax rate (21.0 )% (34.0 )% State income taxes, net of federal benefits (7.0 )% (5.8 )% Non-deductible items (1,418.0 )% 28.5 % Valuation allowance 1,446.0 % 11.3 % Effective income tax rate — % — %

Background (Details)

Background (Details) $ in Thousands	1 Months Ended
	Jul. 31, 2018USD ($)
Background (Textual)
Proceeds from sale of debt securities	$ 500
Proceeds from sale of notes	$ 25

Management's Plans to Continu_2

Management's Plans to Continue as a Going Concern (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Jul. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Management's Plans to Continue as a Going Concern (Textual)
Accumulated deficit	$ (59,746)		$ (59,734)
Cash and cash equivalents and restricted cash balances	$ 331		$ 10	$ 547
Percentage of total assets	90.40%
Amount raised	$ 25	$ 500

Summary of Critical Accountin_4

Summary of Critical Accounting Policies and Use of Estimates (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Shares underlying, outstanding	857,569,880	156,848,198
Shares underlying warrants outstanding [Member]
Shares underlying, outstanding	2,512,930	3,045,740
Shares underlying convertible preferred stock outstanding [Member]
Shares underlying, outstanding	26,395,624	18,324,050
Shares underlying convertible notes outstanding [Member]
Shares underlying, outstanding	828,337,812	135,122,128
Shares underlying options outstanding [Member]
Shares underlying, outstanding	323,514	356,280

Summary of Critical Accountin_5

Summary of Critical Accounting Policies and Use of Estimates (Details 1) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Derivative liability	$ 2,100	$ 2,900
Level 1 [Member]
Derivative liability
Level 2 [Member]
Derivative liability
Level 3 [Member]
Derivative liability	$ 2,134

Summary of Critical Accountin_6

Summary of Critical Accounting Policies and Use of Estimates (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Balance at beginning of year	$ 2,934
Additions to derivative instruments	604	2,952
Reclassification on conversion	(352)	(121)
Loss (gain) on change in fair value of derivative liability	(1,052)	103
Balance at end of period	$ 2,134	$ 2,934

Summary of Critical Accountin_7

Summary of Critical Accounting Policies and Use of Estimates (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Summary of Critical Accounting Policies and Use of Estimates (Textual)
Research and development	$ 208	$ 1,695
Cash and restricted cash	300	10
Impairment charge		332
Depreciation expense	$ 2	23
Goodwill impairment charge		$ 2,200

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Non-cash financial activities:
Common stock issued on conversion of notes payable and derivative liability	$ 503	$ 155
Debentures converted to common stock	361	122
Derivative liability extinguished upon conversion of notes payable	352	121
Derivative liability issued	604	2,952
Net assets and liabilities recognized with the acquisition of Lewis and Clark Pharmaceuticals, Inc.		2,493
Accounts payable paid through issuance of debentures	15	70
Debentures issued to retire preferred stock		2,505
Preferred stock and warrants issued for fees		$ 5

Intellectual Property (Details)

Intellectual Property (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Intellectual Property (Textual)
Payments in cash and common stock	$ 212
Amortization expense	17	$ 17
Amortization expense estimated for two fiscal years	$ 17

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accrued Liabilities, Current [Abstract]
Accrued compensation and benefits	$ 1,326	$ 1,154
Accrued research and development	188	144
Accrued other	300	241
Total accrued expenses	$ 1,814	$ 1,539

Derivative Liability (Details)

Derivative Liability (Details)	Dec. 31, 2018
Volatility [Member]
Derivative liability measurement input	204.00%
Expected term (years) [Member]
Derivative liability term	8 months
Risk-free interest rate [Member]
Derivative liability measurement input	2.59%
Dividend yield [Member]
Derivative liability measurement input

Derivative Liability (Details T

Derivative Liability (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Derivative Liability (Textual)
Gain (loss) on change in fair value of the derivative liability	$ 1,100	$ (100)
Derivative Liability	$ 2,100	$ 2,900

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Feb. 28, 2017	Dec. 31, 2018	Dec. 31, 2017
Commitments and Contingencies (Textual)
Rent expenses		$ 0	$ 52,000
Exercise price
Gross proceeds from capital raising transactions		$ 25,000,000
Dr. Richerson [Member] | Separation Agreement [Member]
Commitments and Contingencies (Textual)
Warrants issued to purchase common stock	76,726
Exercise price	$ 0.75
Option excersice price	$ 0.75
Warrant expiration period	3 years 6 months

Capital Stock and Stockholder_2

Capital Stock and Stockholders' Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 12, 2017	Jul. 31, 2017	Apr. 30, 2017	Mar. 31, 2017	Apr. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2015	Sep. 30, 2018	Jan. 31, 2018	Sep. 30, 2017	Dec. 31, 2016
Capital Stock and Stockholders' Equity (Textual)
Principal amount of senior convertible debentures						$ 361,255
Class of warrant or right, exercise price of warrants or rights
Preferred stock, par value							$ 0.0001		$ 0.0001
Amount of conversion convertible debentures
Preferred stock, outstanding						495	495		495
Reverse stock split, Description						Each share of Series D Preferred Stock held by a Holder, as such, shall be entitled to the whole number of votes equal to 30,001 shares of Common Stock.
Conversion price						$ 0.005				$ 0.0001
Lewis & Clark Pharmaceuticals, Inc. [Member]
Capital Stock and Stockholders' Equity (Textual)
Stock issued during period, shares		7,122,172
Percentage of shares acquired		100.00%
Convertible Preferred Stock [Member]
Capital Stock and Stockholders' Equity (Textual)
Amount of conversion convertible debentures
Number of conversion convertible debentures (in shares)							(118)
Common Stock [Member]
Capital Stock and Stockholders' Equity (Textual)
Amount of conversion convertible debentures
Number of conversion convertible debentures (in shares)							223,585
Warrant [Member]
Capital Stock and Stockholders' Equity (Textual)
Number of common shares purchased			361,734	800,019	361,734
Convertible Debentures [Member]
Capital Stock and Stockholders' Equity (Textual)
Value of number of shares issued							$ 155,153
Number of shares converted							2,144,340
Amount of debentures converted							$ 122,370
Exchange Agreement [Member] | Investors [Member]
Capital Stock and Stockholders' Equity (Textual)
Principal amount of senior convertible debentures	$ 25,000
Share Exchange Agreement [Member] | Lewis & Clark Pharmaceuticals, Inc. [Member]
Capital Stock and Stockholders' Equity (Textual)
Percentage of shares acquired		100.00%
Series A Shares [Member]
Capital Stock and Stockholders' Equity (Textual)
Conversion price						$ 0.53
Number of shares issued upon conversion											79.5
Preferred stock, outstanding						133.81245	133.81245
Series A Shares [Member] | Exchange Agreement [Member] | Series A Convertible Preferred Stock [Member] | Investors [Member]
Capital Stock and Stockholders' Equity (Textual)
Number of shares converted	1,614.8125
Amount of debentures converted	$ 1,600,000
Series B Shares [Member]
Capital Stock and Stockholders' Equity (Textual)
Reduction in conversion price (in dollars per share)						$ 0.02
Number of shares issued upon conversion						90.43418					39
Class of warrant or right, exercise price of warrants or rights						$ 0.02
Preferred stock, outstanding						71	71
Series B Shares [Member] | Exchange Agreement [Member] | Series B 0% Convertible Preferred Stock [Member] | Investors [Member]
Capital Stock and Stockholders' Equity (Textual)
Value of number of shares issued	$ 900,000
Number of shares converted	890
Series C Preferred Stock [Member]
Capital Stock and Stockholders' Equity (Textual)
Reduction in conversion price (in dollars per share)						$ 0.01
Number of shares issued upon conversion						200
Class of warrant or right, exercise price of warrants or rights						$ 0.01
Preferred stock, outstanding						290.43148	290.43148
Series A 0% Convertible Preferred Stock [Member]
Capital Stock and Stockholders' Equity (Textual)
Stock issued during period, shares						1,000		1,853
Beneficial ownership limitation percentage								9.99%
Preferred stock, stated value								$ 1,000
Conversion price								$ 4.50
Subsequent equity sales period								18 months
Number of preferred shares converted to common stock							79.5
Series B 0% Convertible Preferred Stock [Member]
Capital Stock and Stockholders' Equity (Textual)
Number of shares issued upon conversion												1,000
Preferred stock, stated value												$ 1,000
Conversion price												$ 0.75
Number of preferred shares converted to common stock							39
Series C 0% Convertible Preferred Stock [Member]
Capital Stock and Stockholders' Equity (Textual)
Stock issued during period, shares			90.43418	200	290.43148
Value of number of shares issued			$ 90,431	$ 200
Conversion price				$ 0.75	$ 0.75
Number of shares issued upon conversion			387,251	266,673	387,251
Number of common shares purchased			120,578		120,578
Preferred stock, par value			$ 1,000		$ 1,000
Preferred stock, stated value			$ 1,000	$ 1,000	$ 1,000
Common Stock [Member]
Capital Stock and Stockholders' Equity (Textual)
Stock issued during period, shares						73,675,000	223,585
Value of number of shares issued						$ 503,308
Preferred Stock And Warrants [Member]
Capital Stock and Stockholders' Equity (Textual)
Deemed dividend						$ 196	$ 2,204
Series D 0% Convertible Preferred Stock [Member]
Capital Stock and Stockholders' Equity (Textual)
Stock issued during period, shares						5,000
Preferred stock, par value						$ 0.0001
Preferred stock, stated value						$ 1
Series M Common Stock Purchase Warrants [Member]
Capital Stock and Stockholders' Equity (Textual)
Number of common shares purchased			120,578	266,673	120,578
Class of warrant or right, exercise price of warrants or rights			$ 0.90	$ 0.90	$ 0.90
Warrant expiration period			5 years	5 years
Series N Common Stock Purchase Warrants [Member]
Capital Stock and Stockholders' Equity (Textual)
Number of common shares purchased			120,578	266,673	120,578
Class of warrant or right, exercise price of warrants or rights			$ 0.75	$ 0.75	$ 0.75
Warrant expiration period			6 months	6 months
Series O Common Stock Purchase Warrants [Member]
Capital Stock and Stockholders' Equity (Textual)
Number of common shares purchased			120,578	266,673	120,578
Class of warrant or right, exercise price of warrants or rights			$ 0.75	$ 0.75	$ 0.75
Warrant expiration period			12 months	12 months

Stock Options (Details)

Stock Options (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Total stock-based compensation expense	$ 90	$ 202
Research and development [Member]
Total stock-based compensation expense	62	127
General and administrative [Member]
Total stock-based compensation expense	$ 28	$ 75

Stock Options (Details 1)

Stock Options (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of shares
Outstanding at beginning	356,280	268,876
Granted		104,747
Forfeited	(32,766)	(17,343)
Outstanding at ending	323,514	356,280
Exercisable at ending	323,514
Weighted-average exercise price
Outstanding at beginning	$ 7.45	$ 24.1504
Granted		0.54
Forfeited	18.09	41.54
Outstanding at ending	6.28	$ 7.45
Exercisable at ending	$ 6.28
Weighted-average remaining contractual term
Outstanding at ending	3 years 9 months 18 days	4 years 4 months 24 days
Exercisable at ending	3 years 9 months 18 days
Aggregate intrinsic value
Outstanding at ending
Exercisable at ending

Stock Options (Details 2)

Stock Options (Details 2)	12 Months Ended
	Dec. 31, 2018
Expiration period for tax credit
Volatility	128.50%
Expected term (years)	3 years 2 months 12 days
Risk-free interest rate	1.41%
Dividend yield

Stock Options (Details Textual)

Stock Options (Details Textual) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of shares granted		104,747
Number of shares forfited	32,766	17,343
2007 Executive Compensation Plan [Member]
Maximum annual grants	50,000
Number of award authorized	200,000
2007 Executive Compensation Plan [Member] | Common Stock [Member]
Number of shares granted	180,699
Number of shares forfited	111,963
Number of shares available for future issuence	131,264
2009 Executive Compensation Plan [Member]
Number of award authorized	200,000
Number of shares granted	164,868
Number of shares forfited	115,782
Number of shares available for future issuence	150,914
Inducement Award Stock Option Plan [Member]
Number of award authorized	300,000
Number of shares granted	211,360
2017 Equity Compensation Plan [Member]
Number of award authorized	2,000,000
Number of shares available for future issuence	2,000,000
Employee Stock Option [Member] | Employees, And Non-Employee Directors [Member]
Maximum grants under plan		104,747
Weighted Average fair value of the options granted		$ 0.59

Warrants (Details)

Warrants (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Weighted-average remaining contractual term
Exercisable at ending	3 years 9 months 18 days
Aggregate intrinsic value
Outstanding at ending
Exercisable at ending
Warrant [Member]
Number of shares
Outstanding at beginning	3,045,740	5,203,436
Granted		1,238,479
Forfeited	532,810	(3,396,175)
Outstanding at ending	2,512,930	3,045,740
Exercisable at ending	2,512,930
Weighted-average exercise price
Outstanding at beginning	$ 5.39	$ 4.56
Granted		0.08
Forfeited	15.87	1.43
Outstanding at ending	3.16	$ 5.39
Exercisable at ending	$ 3.16
Weighted-average remaining contractual term
Outstanding at ending	2 years 8 months 12 days	3 years 1 month 6 days
Exercisable at ending	2 years 8 months 12 days
Aggregate intrinsic value
Outstanding at ending
Exercisable at ending

Warrants (Details 1)

Warrants (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Weighted Average Exercise price
Warrant [Member]
Number of shares	2,512,930
Consultant [Member] | Warrant [Member]
Number of shares	102,213
Weighted Average Exercise price	$ 7.09
Expiration date begenning	2019-02
Expiration date ending	2023-08
Financing 2014 [Member] | Warrant [Member]
Number of shares	96,412
Weighted Average Exercise price	$ 34.50
Expiration date ending	2019-06
Financing 2015 [Member] | Warrant [Member]
Number of shares	460,384
Weighted Average Exercise price	$ 8.40
Expiration date begenning	2020-07
Expiration date ending	2020-12
Financing 2016 [Member] | Warrant [Member]
Number of shares	1,466,670
Weighted Average Exercise price	$ 0.01
Expiration date ending	2021-12
Financings 2017 [Member] | Warrant [Member]
Number of shares	387,251
Weighted Average Exercise price	$ 0.02
Expiration date begenning	2023-03
Expiration date ending	2022-04

Warrants (Details Textual)

Warrants (Details Textual) - $ / shares	Feb. 28, 2017	Apr. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Exercise price
Series O Common Stock Purchase Warrants [Member]
Number of common shares purchased		387,251	387,251
Warrant expiration period		12 months	12 months
Exercise price		$ 0.75	$ 0.75
Series M Common Stock Purchase Warrants [Member]
Number of common shares purchased		387,251	387,251
Warrant expiration period		5 years	5 years
Exercise price		$ 0.75	$ 0.75
Series N Common Stock Purchase Warrants [Member]
Number of common shares purchased		387,451	387,451
Warrant expiration period		6 months	6 months
Exercise price		$ 0.75	$ 0.75
Series B Preferred Stock [Member]
Exercise price				0.02
Series C Preferred Stock [Member]
Exercise price				$ 0.01
Dr. Richerson [Member] | Separation Agreement [Member]
Warrants issued to purchase common stock	76,726
Warrant expiration period	3 years 6 months
Exercise price	$ 0.75

Convertible Debentures and No_2

Convertible Debentures and Notes (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 03, 2018	Sep. 12, 2017	Apr. 30, 2017	Mar. 31, 2017	Apr. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Jan. 31, 2018
Convertible Debentures and Notes (Textual)
Principal amount of senior convertible debentures						$ 361,255
Conversion price						$ 0.005		$ 0.0001
Securities purchase agreements, description	Pursuant to the Securities Purchase Agreement, we sold an aggregate of $515,000 of senior convertible debentures ("Debentures") consisting of $500,000 in cash and the cancellation of $15,000 of obligations of the Company (the "Offering"). Pursuant to the terms of the Securities Purchase Agreement, we will issue $515,000 in principal amount of Debentures.
Debentures, description	(i) are non-interest bearing, (ii) have a maturity date one (1) year from the date of issuance and (iii) are convertible into shares of our common stock at the election of the Investor at any time, subject to a beneficial ownership limitation of 4.99% which may be increased to 9.99% by the Investor upon 61 days' notice. The Debentures will have a conversion price equal to the lesser of (i) $0.33 and (ii) 85% of the lesser of (a) the volume weighted average price on the trading day immediately preceding a conversion date and (b) the volume weighted average price on a conversion date.
Investors holding, description	Investors holding at least 67% of the then outstanding principal amount of the Debentures, the Company may not (i) amend its charter documents in any manner that adversely affects the rights of any Investor, (ii) repay or repurchase or acquire shares of its Common Stock, (iii) repay, repurchase, or acquire certain indebtedness, or (iv) pay cash dividends or distributions on any equity securities of the Company. The Company is also required under the Securities Purchase Agreement to hold a shareholder meeting by January 3, 2019 in order to increase the number of authorized shares of Common Stock of the Company such that there are sufficient shares of Common Stock available for issuance underlying the Debentures upon their conversion in full. The Company is also obligated under the Securities Purchase Agreement to pay Investors, as partial liquidated damages, a fee of 2.0% of each Investor's initial principal amount of such Investor's Debenture in cash upon our failure to have current public information available beginning six (6) months after the issuance date of the Debentures.
Ownership percentage	50.10%
Description of convertible promissory notes						we issued an aggregate of $25,000 in convertible promissory notes (“Notes”) for cash proceeds of $25,000. The Notes will mature on the earlier of (i) June 30, 2019 or (ii) such time as we raise capital in exchange for the sale of securities (“Maturity Date”) and bear interest at 10% per year, payable on the Maturity Date. Pursuant to the terms of the Notes, the Notes may be converted into shares of common stock upon an Event of Default (as such term is defined in the Notes) or upon the Maturity Date at the election of the holder at a price per share equal to 75% of the lowest trade price of our common stock on the trading day immediately prior to the date such exchange is exercised by the holder.
Convertible debentures [Member]
Convertible Debentures and Notes (Textual)
Conversion price		$ 0.33
Exchange Agreement [Member] | Investors [Member]
Convertible Debentures and Notes (Textual)
Principal amount of senior convertible debentures		$ 25,000
Exchange Agreement [Member] | Convertible debentures [Member]
Convertible Debentures and Notes (Textual)
Payment or cancellation debt		70
Proceeds from debt		320
Received cash from debt		$ 250
Maturity date		Sep. 12, 2018
Discreiption of convertible debentures						The Debentures to be issued to the Investors (i) are non-interest bearing, (ii) have a maturity date of September 12, 2018 and (iii) are convertible into shares of common stock (“Common Stock”) of the Company at the election of the Investor at any time, subject to a beneficial ownership limitation of 4.99% which may be increased to 9.99% by the Investor upon 61 days’ notice. The Debentures will have a conversion price equal to the lesser of (i) $0.33 and (ii) 85% of the lesser of (a) the volume weighted average price on the trading day immediately preceding a conversion date and (b) the volume weighted average price on a conversion date.
Percentage of outstanding debentures						67.00%
Percentage of partial liquidated damages fee for each investor						2.00%
Registration Rights Agreement [Member] | Convertible debentures [Member]
Convertible Debentures and Notes (Textual)
Percentage of partial liquidated damages fee for each investor						1.50%
Percentage of securities issued investors						50.10%
Common Stock [Member]
Convertible Debentures and Notes (Textual)
Common stock,issued						73,675,000	223,585
Common stock,value						$ 503,308
Series A Preferred Stock [Member] | Exchange Agreement [Member] | SeriesAConvertiblePreferredStockMember | Investors [Member]
Convertible Debentures and Notes (Textual)
Number of shares converted		1,614.8125
Amount of shares converted		$ 1,600,000
Series B Preferred Stock [Member] | Exchange Agreement [Member] | Series B 0% Convertible Preferred Stock [Member] | Investors [Member]
Convertible Debentures and Notes (Textual)
Common stock,value		$ 900,000
Number of shares converted		890
Series C 0% Convertible Preferred Stock [Member]
Convertible Debentures and Notes (Textual)
Common stock,issued			90.43418	200	290.43148
Common stock,value			$ 90,431	$ 200

Acquisition (Details)

Acquisition (Details) - Lewis & Clark Pharmaceuticals, Inc. [Member] - Share Exchange Agreement [Member] $ in Thousands	Jul. 31, 2017USD ($)
Cash	$ 23
Prepaid expenses	3
Equipment	353
Goodwill	2,159
Total assets acquired	2,538
Accounts payable and other liabilities	(45)
Total	$ 2,493

Acquisition (Details 1)

Acquisition (Details 1) - Lewis & Clark Pharmaceuticals, Inc. [Member] - Share Exchange Agreement [Member] $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)$ / shares
Revenue
Net loss attributable to common shareholders	$ (13,842)
Net loss per share | $ / shares	$ (1.54)

Acquisition (Details Textual)

Acquisition (Details Textual) - USD ($) $ in Thousands	Jul. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Acquisition (Textual)
Goodwill impairment charge			$ 2,159
Asset impairment charge			332
Lewis & Clark Pharmaceuticals, Inc. [Member]
Acquisition (Textual)
Percentage of ownership acquired	100.00%
Value of revenue and loss			0
Value of revenue and loss			(2,813)
Goodwill impairment charge			2,200
Lewis & Clark Pharmaceuticals, Inc. [Member] | Escrow Agreement [Member]
Acquisition (Textual)
Number of shares held in escrow account	973,251
Lewis & Clark Pharmaceuticals, Inc. [Member] | Share Exchange Agreement [Member]
Acquisition (Textual)
Percentage of ownership acquired	100.00%
Number of shars issued upon acquistion (Purchase consideration)	7,122,172
Number of shares issued upon acquistion, value (Purchase consideration)	$ 2,492,760
Number of shares received by shareholders (5% of the payment shares)	356,109
Goodwill	$ 2,159
Lewis & Clark Pharmaceuticals, Inc. [Member] | Office And Lab Equipment [Member]
Acquisition (Textual)
Asset impairment charge			$ 300

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryover	$ 8,597	$ 8,468
Stock-based compensation	1,920	1,920
Accrued compensation	334	288
Other	30	27
Tax credits	458	458
Total deferred tax assets	11,339	11,161
Less: valuation allowance	(11,339)	(11,161)
Net deferred tax assets

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	(21.00%)	(34.00%)
State income taxes, net of federal benefit	(7.00%)	(5.80%)
Non-deductible items	(1418.00%)	28.50%
Valuation allowance	1446.00%	11.30%
Effective income tax rate

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 22, 2017	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Net operating loss carryforwards			$ 40,300
Expiration period			expire at various dates through 2037.
Research and development tax credits		$ 458	$ 458	$ 458
Expiration period for tax credit			expire from 2028 through 2037.
Increased in valuation allowance			$ 178	$ 832
Federal income tax rate			21.00%	34.00%
Previously federal income tax rate				35.00%
Deferred tax asset, net		$ 6,100
Description of Tax Cuts and Jobs Act	The Tax Cuts and Jobs Act (the "Act"), a tax reform bill, was enacted. The Act, among other items, reduces the current federal income tax rate to 21% from 35%. The rate reduction is effective January 1, 2018, and is permanent.

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Thousands	Jul. 05, 2019	Jan. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Subsequent Events (Textual)
Number of common shares issued			84,563,929	10,888,929
Subsequent Event [Member]
Subsequent Events (Textual)
Number of common shares issued		65,436,071
Amount of debentures converted		$ 204,221
Shares issued		5,000
Proceeds from convertible preferred stock		$ 5,000
Subsequent event, description	Effective July 5, 2019, Sabby Healthcare Master Fund, Ltd and Sabby Volatility Warrant Master Fund, Ltd. waived certain events of default under debentures issued in our July 2018 debenture offering and September 2017 debenture offering (collectively, the “Debenture Offerings”) and extended the maturity date of such debentures until September 30, 2019 in exchange for the issuance of $154,000 in new debentures with substantially the same terms as those issued in our Debenture Offerings.